Definition
A sub-anesthetic dose of ketamine is any dose below the threshold required to produce general anesthesia. In the context of depression treatment, this typically refers to intravenous doses of approximately 0.5 mg/kg administered over 40 minutes, or equivalent doses by other routes. At these levels, ketamine produces antidepressant and anti-suicidal effects without rendering the patient unconscious, though mild to moderate dissociative and perceptual effects are common.
Anesthetic vs Sub-Anesthetic Dosing
Ketamine was originally developed and FDA-approved in 1970 as an anesthetic agent. Anesthetic doses for surgical procedures typically range from 1.0 to 4.5 mg/kg intravenously for induction, with additional doses or continuous infusion to maintain anesthesia. At these levels, ketamine produces complete dissociative anesthesia — a trance-like state with profound analgesia and amnesia while the patient's cardiovascular and respiratory functions remain relatively stable.
Sub-anesthetic doses, by contrast, are typically one-quarter to one-tenth of anesthetic doses. The most studied antidepressant dose — 0.5 mg/kg IV over 40 minutes — was established by the landmark 2000 study by Berman et al. at Yale University and has since become the standard protocol in hundreds of clinical trials. At this dose, patients remain conscious, can communicate, and breathe independently, though they commonly experience transient effects including:
- Mild dissociation (feeling detached from one's body or surroundings)
- Perceptual changes (visual distortions, altered sense of time)
- Lightheadedness or dizziness
- Nausea
- Transient increases in blood pressure and heart rate
These effects typically resolve within one to two hours after the infusion ends.
The Therapeutic Window
The concept of a sub-anesthetic therapeutic window is central to ketamine's use in psychiatry. Research suggests that the antidepressant mechanism operates optimally within a relatively narrow dose range. Doses that are too low may not produce sufficient NMDA receptor blockade to trigger the downstream cascade of glutamate release, BDNF signaling, and synaptogenesis that underlies the antidepressant effect. Doses that are too high may produce excessive dissociation, more pronounced side effects, and potentially diminished therapeutic benefit.
Studies have explored doses ranging from 0.1 mg/kg to 1.0 mg/kg IV. The 0.5 mg/kg dose has consistently shown the most robust antidepressant effects, though some patients respond to lower doses and others may benefit from modest dose adjustments upward. A 2014 dose-finding study published in Biological Psychiatry tested multiple dose levels and confirmed that 0.5 mg/kg produced the strongest and most reliable antidepressant response.
Dosing by Route of Administration
Because first-pass metabolism and bioavailability differ substantially across routes, sub-anesthetic doses vary accordingly:
- Intravenous: 0.5 mg/kg over 40 minutes (the gold-standard research dose)
- Intramuscular: 0.5 to 1.0 mg/kg (higher dose due to slightly lower bioavailability)
- Sublingual/troche: 0.5 to 2.0 mg/kg (bioavailability approximately 25 to 30 percent)
- Oral: 1.0 to 3.0 mg/kg (bioavailability approximately 17 to 24 percent)
- Intranasal (esketamine): 56 to 84 mg fixed dose (the FDA-approved protocol)
All of these remain well below anesthetic thresholds when administered according to clinical protocols.
Safety Considerations
Sub-anesthetic ketamine is generally well tolerated, but clinical administration typically includes monitoring of vital signs (blood pressure, heart rate, oxygen saturation) during and after treatment. Patients are usually observed for one to two hours post-treatment and are advised not to drive for the remainder of the day. The transient hemodynamic effects — modest increases in blood pressure and heart rate — are usually clinically insignificant in healthy patients but require attention in those with uncontrolled hypertension or cardiovascular disease.
References
- Antidepressant Effects of Ketamine in Depressed Patients — Berman et al. (2000), Biological Psychiatry. First controlled trial establishing the 0.5 mg/kg dose.
- A Dose-Ranging Study of Intravenous Ketamine — Fava et al. (2020), Biological Psychiatry. Dose-finding study confirming optimal antidepressant dose.
- Ketamine Dosing for Depression: A Review — NIH review of ketamine dosing across routes of administration.
Share